☆ 4.8 Article

SARS-CoV-2 vaccine breakthrough infections with the alpha variant are asymptomatic or mildly symptomatic among health care workers

NATURE COMMUNICATIONS (2021)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Virology

Quantifying the risk of SARS-CoV-2 reinfection over time

Eamon O. Murchu et al.

Summary: The study found that SARS-CoV-2 reinfection is not common, with a relatively low risk of reinfection, and there is no evidence to suggest an increase in reinfection risk over time. Whole genome sequencing in a subset of patients showed a low population-level risk of reinfection, with no evidence of waning immunity for up to 7 months following primary infection.

REVIEWS IN MEDICAL VIROLOGY (2022)

添加到收藏夹

Article Medicine, General & Internal

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey et al.

Summary: The ChAdOx1 nCoV-19 vaccine has been shown to have an acceptable safety profile and effectiveness against symptomatic COVID-19, with higher efficacy observed in the group that received a low dose followed by a standard dose.

LANCET (2021)

添加到收藏夹

Article Multidisciplinary Sciences

Genomic epidemiology of SARS-CoV-2 reveals multiple lineages and early spread of SARS-CoV-2 infections in Lombardy, Italy

Claudia Alteri et al.

Summary: The Lombardy region of Italy was heavily affected early in the SARS-CoV-2 pandemic. Using whole genome sequencing, researchers found multiple virus introductions into the region with transmission occurring before the first case was detected.

NATURE COMMUNICATIONS (2021)

添加到收藏夹

Letter Medicine, General & Internal

Antibody response to first BNT162b2 dose in previously SARS-CoV-2-infected individuals

Charlotte Manisty et al.

LANCET (2021)

添加到收藏夹

Letter Medicine, General & Internal

Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine

Maria Prendecki et al.

LANCET (2021)

添加到收藏夹

Letter Medicine, General & Internal

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

Sharon Amit et al.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Letter Public, Environmental & Occupational Health

No evidence of SARS-CoV-2 circulation in the framework of influenza surveillance between October 2019 and February 2020 in Lombardy, Italy

Federica Giardina et al.

TRAVEL MEDICINE AND INFECTIOUS DISEASE (2021)

添加到收藏夹

Article Infectious Diseases

SARS-CoV-2 specific T-cell immunity in COVID-19 convalescent patients and unexposed controls measured by ex vivo ELISpot assay

Irene Cassaniti et al.

Summary: The study evaluated the SARS-CoV-2 T-cell response in COVID-19 convalescent patients and unexposed individuals, showing that a majority of convalescent patients had a positive response to at least one SARS-CoV-2 antigen, which could last up to 12 months. The findings suggest that the SARS-CoV-2 T-cell response is primarily mediated by CD4 T cells.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

添加到收藏夹

Article Medicine, General & Internal

Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers

Yoel Angel et al.

Summary: This cohort study in Tel Aviv, Israel, found that vaccination with the Pfizer-BioNTech BNT162b2 vaccine was significantly associated with a lower incidence of symptomatic and asymptomatic SARS-CoV-2 infection among health care workers more than 7 days after the second dose.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

添加到收藏夹

Article Medicine, General & Internal

Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study

Eleftheria Vasileiou et al.

Summary: The study in Scotland found that the first doses of the BNT162b2 mRNA and ChAdOx1 vaccines were associated with substantial reductions in the risk of COVID-19 hospital admission, with vaccine effectiveness ranging from 88% to 91% at 28-34 days post-vaccination.

LANCET (2021)

添加到收藏夹

Article Medicine, General & Internal

Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data

Eric J. Haas et al.

Summary: This study assessed the real-world effectiveness of the Pfizer-BioNTech mRNA COVID-19 vaccine BNT162b2 in Israel, showing high efficacy in preventing SARS-CoV-2 infections, hospitalizations, severe disease, and death. As vaccine coverage increased, there were marked declines in SARS-CoV-2 outcomes, indicating that COVID-19 vaccination can help control the pandemic.

LANCET (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine

Matan Levine-Tiefenbrun et al.

Summary: COVID-19 vaccines not only provide protection to individual vaccinees, but may also reduce viral load in breakthrough infections, potentially leading to lower infectiousness and further suppressing virus spread.

NATURE MEDICINE (2021)

添加到收藏夹

Article Medicine, General & Internal

Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study

Jamie Lopez Bernal et al.

Summary: This study estimated the real-world effectiveness of Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S vaccines against confirmed COVID-19 symptoms, hospital admissions, and deaths. The vaccines showed significant reduction in symptomatic COVID-19 among older adults and further protection against severe disease. Both vaccines demonstrated similar effects and protection was maintained for over 6 weeks.

BMJ-BRITISH MEDICAL JOURNAL (2021)

添加到收藏夹

Article Public, Environmental & Occupational Health

Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers - Eight US Locations, December 2020-March 2021

Mark G. Thompson et al.

MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT (2021)

添加到收藏夹

Article Infectious Diseases

Incidence of SARS-CoV-2 infection in health care workers from Northern Italy based on antibody status: immune protection from secondary infection- A retrospective observational case-controlled study

Francesca Rovida et al.

Summary: The study evaluated the protective effect of SARS-CoV-2 anti-S1 and anti-S2 IgG antibody positivity induced by natural infection against SARS-CoV-2 infection. The results showed that immunity from natural infection can reduce the risk of secondary infection and alleviate symptoms.

INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Biochemistry & Molecular Biology

Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom

Emma Pritchard et al.

Summary: Results from the Office for National Statistics COVID-19 Infection Survey in the UK demonstrate that the ChAdOx1 nCoV-19 and BNT162b2 vaccines reduce the incidence of new SARS-CoV-2 infections by up to 65% with a single dose and up to 80% after two doses, with no significant differences in efficacy observed between the two vaccines.

NATURE MEDICINE (2021)

添加到收藏夹

Editorial Material Medicine, General & Internal

Covid-19-The Search for Effective Therapy

Lindsey R. Baden et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Article Infectious Diseases

Prevalence of SARS-CoV-2 specific neutralising antibodies in blood donors from the Lodi Red Zone in Lombardy, Italy, as at 06 April 2020

Elena Percivalle et al.

EUROSURVEILLANCE (2020)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.